# The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Study · id `cardio:ct-nct01975376` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01975376](<https://clinicaltrials.gov/study/NCT01975376>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01975376

Browse, organ or system: Heart; Brain; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Stroke; Diabetes and metabolic disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 16784 participants.

## Technical summary

Registry record NCT01975376. Randomized; quadruple masking; primary purpose prevention. Start 2013-10-29 (actual); primary completion 2017-03-22 (actual). Results posted on 2018-06-12.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 16784 participants (enrolled count; ClinicalTrials.gov record NCT01975376, source copy `cardio:ctgov-nct01975376-2018-07-11`, retrieved 2026-10-26)
- Started: 2013-10-29 (actual) (ClinicalTrials.gov record NCT01975376, source copy `cardio:ctgov-nct01975376-2018-07-11`, retrieved 2026-10-26)
- Primary completion: 2017-03-22 (actual) (ClinicalTrials.gov record NCT01975376, source copy `cardio:ctgov-nct01975376-2018-07-11`, retrieved 2026-10-26)
- Completion: 2017-03-22 (actual) (ClinicalTrials.gov record NCT01975376, source copy `cardio:ctgov-nct01975376-2018-07-11`, retrieved 2026-10-26)
- Results first posted: 2018-06-12 (ClinicalTrials.gov record NCT01975376, source copy `cardio:ctgov-nct01975376-2018-07-11`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Belgium; Brazil; Canada; Chile; China; Colombia; Czechia; Denmark; Finland; France; Germany; Hungary; India; Ireland; Israel; Italy; Mexico; Netherlands; New Zealand; Poland; Puerto Rico; Romania; Russia; Slovakia; South Africa; South Korea; Spain; Sweden; Switzerland; Taiwan; Thailand; Türkiye; United Kingdom (ClinicalTrials.gov record NCT01975376, source copy `cardio:ctgov-nct01975376-2018-07-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01975376-2018-07-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
- Acronym: SPIRE-1
- Condition: Cardiovascular Disease
- Intervention (Drug): bococizumab (PF-04950615)
- Intervention (Drug): Placebo
- Lead sponsor: Pfizer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Pfizer (`cardio:org-pfizer`)

## Provenance

Content hash: 5d9eeae7a0511b1b63f1e7e6d581e1e459a9a1a0f5b855dafe1be8cbd66a306e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
